Bristol Myers Squibb Joins Forces to Challenge Medicare’s Drug Price Negotiation Program
Bristol Myers Squibb (BMS), a leading U.S. pharmaceutical company, has joined the growing list of organizations filing a legal challenge against the Medicare drug price negotiation program established by the Inflation Reduction Act (IRA). In line with similar complaints filed by Merck & Co. and the Chamber of Commerce, BMS argues that the provision in …